Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Recent:Uckun Farmanpour-Kalalagh Trieu.
Artemisinin was adopted
in 13 countries.
Submit updates/corrections .
Summary.
Mar 7 |
Artemisinin reduces COVID-19 risk: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for recovery. One study shows significant benefit. Meta analysis using the most serious outcome reported shows 34% [11‑51%] lower risk. Results are similar for peer-reviewed studies and better f.. | ||
Nov 15 2024 |
et al., Molecules, doi:10.3390/molecules29225403 | Insights into SARS-CoV-2: Small-Molecule Hybrids for COVID-19 Treatment |
| Review of recent advances in small-molecule hybrid compounds as potential antiviral agents against SARS-CoV-2. Authors provide an overview of hybrids, which are formed by covalently linking two or more pharmacophores, as a promising appro.. | ||
Oct 26 2024 |
et al., Molecular Biology Research Communications, doi:10.22099/mbrc.2024.50245.2001 | Non-spike protein inhibition of SARS-CoV-2 by natural products through the key mediator protein ORF8 |
| In Silico study showing that ivermectin, artemisinin, and DEG-168 may inhibit SARS-CoV-2 by targeting the ORF8 protein's binding sites. Ivermectin showed the highest binding affinity. Authors identified two key binding regions on ORF8 - a.. | ||
May 18 2024 |
et al., NCT04330690 | A Multi-centre, Adaptive, Randomized, Open-label, Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients (CATCO: Canadian Treatments for COVID-19), in Conjunction With the Public Health Emergency SOLIDARITY Trial (World Health Organization) |
| Estimated 966 patient artemisinin late treatment RCT with results not reported over 9 months after estimated completion. | ||
May 15 2024 |
et al., BMC Infectious Diseases, doi:10.1186/s12879-024-09387-w | Phytoconstituents of Artemisia Annua as potential inhibitors of SARS CoV2 main protease: an in silico study |
| In Silico study showing that artemisinin and artesunate from Artemisia annua bind to the SARS-CoV-2 main protease (Mpro), with artesunate exhibiting a binding score of -7.5 kcal/mol. Authors screened 25 phytoconstituents, identifying arte.. | ||
Jan 2 2024 |
et al., PeerJ, doi:10.7717/peerj.15638 | Chemical and spectroscopic characterization of (Artemisinin/Quercetin/ Zinc) novel mixed ligand complex with assessment of its potent high antiviral activity against SARS-CoV-2 and antioxidant capacity against toxicity induced by acrylamide in male rats |
| In Vitro and animal study showing that a novel artemisinin/quercetin/zinc (Art/Q/Zn) complex exhibits potent anti-SARS-CoV-2 activity (IC50 = 10.14 μg/ml) without cytotoxicity (CC50 = 208.5 μg/ml). The complex alleviates acrylamide-induce.. | ||
Dec 1 2022 |
et al., NCT05273242 | WHO Solidarity Trial Plus: An International Randomised Trial of Additional Treatments for COVID-19 in Hospitalised Patients Who Are All Receiving the Local Standard of Care in Nepal |
| Estimated 400 patient artemisinin late treatment RCT with results not reported over 2 years after estimated completion. | ||
Nov 1 2022 |
et al., eBioMedicine, doi:10.1016/j.ebiom.2022.104322 | Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial |
| 29% lower progression (p=0.66), 27% faster recovery (p=0.1), and 1% worse viral clearance (p=0.76). Very high COI low-risk patient RCT in South Africa, showing no significant differences with artesunate-amodiaquine or pyronaridine-artesunate. | ||
Feb 7 2022 |
et al., Frontiers in Plant Science, doi:10.3389/fpls.2022.780257 | Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand |
| Review of artemisinin and related compounds (artemisinins) for their potential in combating viral infections, inflammation, and cancers, with a special focus on SARS-CoV-2/COVID-19. Authors explain that artemisinin, a sesquiterpene lacton.. | ||
Mar 19 2021 |
et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.649532 | Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug |
| Review of artemisinin, an anti-malaria phytomedicine with anti-inflammatory properties, as a potential COVID-19 drug. Authors explain that artemisinin, discovered by Nobel laureate Tu Youyu, shows broad-spectrum antiviral activity and spe.. | ||
Feb 1 2021 |
et al., medRxiv, doi:10.1101/2021.01.24.21250418 | Targeting TGF-β pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 |
| 52% improved recovery (p=0.08). RCT 60 mild-moderate COVID-19 patients showing faster recovery with artemisinin. | ||
Apr 28 2020 |
et al., China Critical Care Medicine, doi:10.3760/cma.j.cn121430-20200312-00412 | Clinical study of artesunate in the treatment of coronavirus disease 2019 |
| 31% faster recovery (p=0.02), 8% shorter hospitalization (p=0.22), and 29% faster viral clearance (p=0.05). Prospective study of 43 hospitalized COVID-19 patients in China showing faster symptom improvement and shorter hospitalization with artesunate. Artesunate 60 mg twice daily for 10 days. | ||
Apr 24 2020 |
et al., ChemRxiv, doi:10.26434/chemrxiv.12181404.v1 | In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2 |
| In Silico study of natural compounds identifying quercetin, curcumin, hispidulin, cirsimaritin, sulfasalazine, and artemisin as potential compounds that inhibit SARS-CoV-2. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.